Ms. LilyWhat can I do for you?
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
Company Info
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
Business Type:
Manufacturer , Trade Company , Distributor/Wholesaler
Main Products:
API , Raw Material Pharma , Pharmaceutical Intermediates , Active Pharmaceutical Ingredients , Agrochemical Intermediates , Fine Chemicals
Export Percentage:
81% - 90%
Year Established:
2014
New Products
Company News
Chinese Covid-19 vaccine candidate shows promise in human trial: Study
2020 / 10 / 19
The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years and found that antibody responses were induced in all recipients. BEIJING: One of China's leading Covid-19 vaccine candidates, called BBIBP-CorV, was shown to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday. A previous clinical trial reported similar results for a different vaccine that is also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only tested in people aged under 60 years. The latest study, published in The Lancet Infectious Diseases journal, included participants aged between 18 and 80 years, and found that antibody responses were induced in all recipients.
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
2019 / 09 / 03
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis FOSTER CITY, Calif.--Jul. 19, 2019--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
Merck Potential met New Drug for Lung Cancer Submitted to ind China
2019 / 08 / 28
.Tepotinib film officially submitted a new drug IND in China: Tepotinib tablets are an oral MET inhibitor. Preclinical data show that Tepotinib can overcome the acquired resistance to EGFR-TKI due to abnormal MET activation, and theoretically improve the efficacy of patients with MET-positive EGFR-TKI-resistant NSCLC. Note: MET positive generally refers to MET overexpression and / or MET gene amplification Wherein MET overexpression is defined as immunohistochemistry IHC 2-3+; MET gene amplification is defined as in situ hybridization (ISH) detection of gene copy number (GCN) ≥ 5 and or MET / CEP7 ≥ 2.
Send Inquiry
Ms. Lily
Tel:86-311-67260775
Fax:86-311-67591193
Mobile Phone:+8615933619867
Email:sales@dingminpharma.com
Address:No.52 Zhaiying South Street,Yuhua District, Shijiazhuang, Hebei
Related Products List
Mobile Site
